BioSpace News Archive

Medivir AB announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma.

Over 34 million American adults currently live with diabetes and an additional 88 million are living with prediabetes, yet 85% of them do not know they have it.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy Opdivo is the first and only immunotherapy approved in this patient population In CheckMate -577, Opdivo doubled median disease-free survival versus placebo for these patients 1

Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announcedthat it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE™ database.

Ribometrix, Inc., a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced that the company was honored to receive the Triangle Business Journal’s 2021 Life Sciences Award for “Best Early-Stage Product Development Company.”

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference

Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 which includes a webcast beginning at 9:00 a.m. ET . The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/e

Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for TN-201, its most advanced product candidate from its proprietary Gene Therapy Platform.